- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab, Ipilimumab, Ipilimumab placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Athens, Georgia • Boston, Massachusetts + 2 more
Bristol-Myers Squibb clinical trials
Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Live official records
Open in full search- Conditions
- Leukemia, Lymphoma
- Interventions
- Dasatinib (BMS-354825)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986460
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Greg Durm, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Louisville, Kentucky + 8 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986288, Nivolumab, Regorafenib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 6
- States / cities
- Costa Mesa, California • Orange, California • Aurora, Colorado + 3 more
- Conditions
- Lung Cancer, SCLC
- Interventions
- Nivolumab, Plinabulin, Ipilimumab
- Drug
- Lead sponsor
- Salma Sabbour
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan
- Conditions
- AML
- Interventions
- Venetoclax, CC-486
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Participants
- Interventions
- Admilparant
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Hepatic Insufficiency, Neoplasms
- Interventions
- Onureg
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Elotuzumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- Denver, Colorado • St Louis, Missouri
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Nivolumab, Cisplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Sue Yom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
About this Bristol-Myers Squibb sponsor directory page
- What this page lists
- U.S. ClinicalTrials.gov public records where Bristol-Myers Squibb is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bristol-Myers Squibb trials.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.
Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Bristol-Myers Squibb.